北京大学学报(医学版) ›› 2015, Vol. 47 ›› Issue (4): 685-689. doi: 10.3969/j.issn.1671-167X.2015.04.027

• 论著 • 上一篇    下一篇

地塞米松对新辅助化疗后乳腺癌患者术后恶心呕吐发生率的影响

李志红*,刘丹*,何自静,范志毅△   

  1. (北京大学肿瘤医院,北京市肿瘤防治研究所麻醉科;恶性肿瘤发病机制及转化研究教育部重点实验室,北京 100142)
  • 出版日期:2015-08-18 发布日期:2015-08-18
  • 通讯作者: 范志毅 E-mail:13911114196@163.com

Influence of dexamethasone on the incidence of postoperative nausea and vomiting in breast cancer patients with neoadjuvant chemotherapy

LI Zhi-hong*, LIU Dan*, HE Zi-jing, FAN Zhi-yi△   

  1. [Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Anesthesiology, Peking University Cancer Hospital & Institute, Beijing 100142, China]
  • Online:2015-08-18 Published:2015-08-18
  • Contact: FAN Zhi-yi E-mail:13911114196@163.com

摘要:

目的:评估地塞米松对新辅助化疗(术前化疗)后乳腺癌改良根治术术后恶心呕吐(postoperative nausea and vomiting, PONV)的预防效果。方法:新辅助化疗后行乳腺癌改良根治术的女性乳腺癌患者280例,18~60岁,随机分为两组,每组140例:(1)D组:实验组,术前给予10 mg地塞米松静脉滴注;(2)C组:对照组,术前给予2 mL生理盐水作为安慰剂静脉滴注。每组患者再分为两亚组,每组70例,分别应用丙泊酚全凭静脉麻醉(total intravenous anesthesia, TIVA)(P亚组)和七氟醚维持吸入全身麻醉(S亚组)。所有患者均进行标准的全身麻醉操作,手术结束前30 min静脉滴注昂丹司琼(ondansetron) 8 mg。随访术后24 h内患者恶心呕吐的发生率,并对PONV的影响因素进行Logistic回归分析。检测因素包括年龄、体重指数(body mass index, BMI)、手术时间、术后疼痛程度、晕动病史/既往PONV史、是否应用地塞米松以及麻醉方法。结果:术后24 h内D组患者恶心呕吐的发生率明显低于C组患者(11.4% vs. 20.7%,P=0.034);术后0~2 h D组患者PONV的发生率低于C组患者(1.4% vs. 6.4%,P=0.031);术后2~24 h D组患者PONV的发生率与C组患者差异无显统计学意义(10.7% vs. 17.9%,P=0.088)。术后24 h内各时段,D组与C组内丙泊酚全凭静脉麻醉亚组与吸入麻醉亚组PONV的发生率比较差异均无统计学意义(P>0.05)。Logistic回归分析显示地塞米松对新辅助化疗后乳腺癌改良根治术患者术后恶心呕吐有预防效果(OR=0.447,P=0.030),晕动症/PONV病史是术后恶心呕吐的危险因素(OR=15.730,P<0.001)。结论:术前应用地塞米松可明显降低新辅助化疗后乳腺癌改良根治术患者术后恶心呕吐的发生率。

关键词: 手术后恶心呕吐, 新辅助治疗, 地塞米松, 丙泊酚, 乳房切除术, 改良根治性

Abstract:

Objective:To evaluate the influence of dexamethasone on the incidence of postoperative nausea and vomiting (PONV) in patients undergoing modified radical mastectomy with neoadjuvant chemotherapy. Methods:In a prospective trial, 280 female (18-60 years) breast cancer patients undergoing modified radical mastectomy with neoadjuvent chemotherapy were randomized to two groups: one with dexamethasone (Group D) and one without dexamethasone (Group C, n=140). In each group, anesthesia was maintained with volatile anesthesia or total intravenous anesthesia (TIVA): TIVA (propofol) without dexamethasone (Subgroup CP); volatile anesthesia (sevoflurane) without dexamethasone (Subgroup CS); TIVA with 10 mg dexamethasone intravenously before anesthetic induction (Subgroup DP); volatile anesthesia with 10 mg dexamethasone intravenously before anesthetic induction (Subgroup DS). A standard general anesthetic technique was used. All the patients received 8 mg of ondansetron intravenously 30 minutes before the end of surgical procedures. The incidence of PONV during the 24-hour postoperative period was recorded. A Logistic regression analysis was conducted to examine relevant factors for PONV . The tested factors were: age, body mass index (BMI), duration of surgery, postoperative pain, history of motion sickness/PONV, with or without dexamethasone and anesthetic regimen.Results:There was a significant lower incidence of PONV in the patients who received dexamethasone than in those who received placebo during the 24-hour postoperative period (11.4% vs. 20.7%,P=0.034). In the early postoperative period (0-2 h) dexamethasone reduced the incidence of PONV ( 1.4%vs.6.4%, P=0.031),but in the late postoperative period (2-24 h) the difference of the incidence was insignificantly (10.7% vs. 17.9%, P=0.088). No differences were found between TIVA and volatile anesthesia in the 24hour postoperative period. Dexamethasone was effective to prevent PONV(OR=0.447,P=0.030), and history of PONV or motion sickness was the risk factor of PONV (OR=15.730,P<0.001). Conclusion:Dexamethasone prevents PONV effectively in patients undergoing modified radical mastectomy with neoadjuvant chemotherapy, and TIVA cannot decrease the incidence of PONV in the 24hour postoperative period in those patients.

Key words: Postoperative nausea and vomiting, Neoadjuvant therapy, Dexamethasone, Propofol, Mastectomy, modified radical

中图分类号: 

  • R614.2
[1] 马建勋,夏有辰,李比,赵红梅,雷玉涛,布希. 乳腺癌改良根治术后即刻乳房重建的方式选择[J]. 北京大学学报(医学版), 2023, 55(4): 612-618.
[2] 熊焰,张波,聂立功,吴世凯,赵虎,李东,邸吉廷. 胸部SMARCA4缺失性未分化肿瘤的病理诊断与联合免疫检测点抑制剂治疗[J]. 北京大学学报(医学版), 2023, 55(2): 351-356.
[3] 史成梅,周阳,杨宁,李正迁,陶一帆,邓莹,郭向阳. 丙泊酚用于无痛胃肠镜检查对患者术后精神活动的影响[J]. 北京大学学报(医学版), 2023, 55(2): 324-327.
[4] 史成梅,王雪冬,刘又鲲,邓莹,郭向阳. 地塞米松联合盐酸奥布卡因凝胶用于预防鼻内镜术后咽喉痛[J]. 北京大学学报(医学版), 2022, 54(2): 289-293.
[5] 王立新, 许晓, 倪耀丰, 孙海涛, 余日月, 魏世成. 载药脂质体修饰的聚醚醚酮植入物的抑菌和骨整合性能[J]. 北京大学学报(医学版), 2021, 53(4): 758-763.
[6] 张威,叶颖江,任仙文,黄晶,申占龙. 利用转录组二代测序探索直肠癌术前放化疗的敏感性分子特征[J]. 北京大学学报(医学版), 2019, 51(3): 542-547.
[7] 张喆,居瑞军,李学涛,张东晓,吴仁荣,陈学军,吕万良. 葡萄糖基化丙泊酚溶液型注射剂在大鼠体内的药物动力学[J]. 北京大学学报(医学版), 2015, 47(5): 846-852.
[8] 马泽云, 王衣祥. 建立大鼠双膦酸盐相关颌骨骨坏死模型并初步分析其发病原因[J]. 北京大学学报(医学版), 2014, 46(6): 945-949.
[9] 关明,王恩博,刘宇,张伟. 丙泊酚靶控输注联合芬太尼静脉镇静拔除下颌阻生智齿的效果评价[J]. 北京大学学报(医学版), 2014, 46(1): 107-110.
[10] 杨璐, 魏滨, 张利萍, 毕姗姗, 卢炜, 郭向阳. 丙泊酚和瑞芬太尼在抑制强直电刺激中的药效学相互作用[J]. 北京大学学报(医学版), 2010, 42(5): 547-553.
[11] 林琴, 王广发, 汤秀英, 邹水兰. 地塞米松对内毒素致急性肺损伤大鼠肺的保护作用[J]. 北京大学学报(医学版), 2006, 38(4): 393-396.
[12] 许川雅, 吴新民, 蒋建渝. 老年患者靶控输注瑞芬太尼和丙泊酚的临床评价[J]. 北京大学学报(医学版), 2005, 37(5): 513-515.
[13] 王治军, 许幸, 吴新民. 地塞米松、甘露醇对大鼠全脑缺血再灌注损伤的治疗作用[J]. 北京大学学报(医学版), 2003, 35(3): 303-306.
[14] 范志毅, 马琼, 王庚. 丙泊酚与硫喷妥钠全麻诱导的血流动力学及儿茶酚胺反应的比较[J]. 北京大学学报(医学版), 2001, 33(6): 576-576.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!